Image may be NSFW.
Clik here to view.
Delcath Systems (NSDQ:DCTH) touted data today from a study of its second-generation hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan hydrochloride.
The New York-based company presented the results from its study at the Cardiology and Interventional Radiology of Europe annual meeting in Copenhagen, Denmark.
The investigational product, an injectable melphalan hydrochloride for use with Delcath’s hepatic delivery system, is designed to administer high-dose chemotherapy to the liver while limiting systemic exposure and side effects.
Get the full story at our sister site, Drug Delivery Business News.
The post CIRSE 2017 Round-up: Delcath touts second-gen hemofiltration system in percutaneous hepatic perfusion appeared first on MassDevice.
